Adherium Limited (ASX: ADR), a leader in respiratory eHealth, remote monitoring and data management solutions, today announced that it has been awarded a contract for supply of the Hailie® solution to an upcoming US-based clinical study by AstraZeneca.
Adherium will be providing a bespoke version of its Hailie® sensor and software to track the usage of the investigational inhaler medications via the study participants’ phones. The sensors and software will be supplied for commencement of the study during FY2022, generating approximately US$650,000 in revenue, and further support services will be supplied over the course of the study’s two-year duration.
Rick Legleiter, Adherium’s CEO commented “Adherium has a longstanding clinical study supply relationship with AstraZeneca to support the collection of objective clinical trial data using Adherium’s Hailie® technology. This is welcome revenue as Adherium progresses its strategy focusing on a provider and payor model and expanding its revenue base over multiple channels.”
The contract for the clinical study is on usual commercial terms and is in addition to the 10-year Master Supply and Development Agreement entered into with AstraZeneca in July 2015.